The Journal of Precision Medicine
PMLS
PMLS
BMS
BMS

About adminpmls2016

This author has not yet filled in any details.
So far adminpmls2016 has created 54 blog entries.

Tempus xF Liquid Biopsy Assay Demonstrates Extensive Analytical and Clinical Validity in npj Precision Oncology Study

2021-07-14T07:59:04-05:00July 14th, 2021|

Tempus, a leader in artificial intelligence and precision medicine, today announced results from validation studies demonstrating the reliable analytical performance of the Tempus|xF liquid biopsy. When validated against methods such as ddPCR, the Roche AVENIO kit, and the Tempus|xT solid tumor assay, xF demonstrated high sensitivity and specificity for calling SNVs, indels, CNVs, and [...]

Novartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts

2021-07-14T07:56:30-05:00July 14th, 2021|

Novartis and Hewlett Packard Enterprise (HPE) today announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to healthcare and medicines. The collaboration will focus on three global health enablers: identifying and integrating complex data sources related to health; advancing [...]

Dr. Eric Walk Joins PathAI as Chief Medical Officer

2021-07-14T07:53:42-05:00July 14th, 2021|

PathAI, a leading provider of AI-powered technology for advancing pathology research, announced that it has appointed Pathologist and executive leader Eric Walk, MD, FCAP, as Chief Medical Officer. "The PathAI team is excited to welcome Dr. Eric Walk onto our leadership team," said Andrew Beck. "Eric brings decades of experience working in the global [...]

Thermo Fisher Scientific Expands Corporate Leadership Team

2021-07-11T18:47:39-05:00July 11th, 2021|

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has announced that Alan Sachs, who has served as chief scientific officer (CSO) since 2016, will assume the newly established role of chief medical officer (CMO) and will be succeeded by Karen E. Nelson, previously president of the J. Craig Venter Institute. Both [...]

Agilent Announces New SureSelect Human All Exon V8

2021-06-04T13:53:57-05:00June 4th, 2021|

Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein-coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The [...]

New Research from Caris Life Sciences Finds Immunotherapy Resistance in Leiomyosarcoma

2021-06-04T13:36:10-05:00June 4th, 2021|

Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, to present findings that provide a deeper understanding of how immunotherapies (IO) affect leiomyosarcoma (LMS), a rare cancer that affects smooth muscle tissue, through the use of whole exome and whole transcriptome sequencing. These [...]

Labcorp to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting

2021-06-04T13:31:37-05:00June 4th, 2021|

Labcorp (NYSE: LH), a leading global life sciences company, today announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO®) Annual Meeting held June 4-8. Labcorp’s oncology platform brings together the company’s leadership in diagnostic testing with its comprehensive drug development services, delivering targeted solutions [...]

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

2021-06-04T13:27:57-05:00June 4th, 2021|

Novartis today announced the first published mature overall survival (OS) and updated overall response rate (ORR) data following treatment with Tabrecta® (capmatinib) in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14)1-3. Data from the ongoing, pivotal, multi-cohort Phase II GEOMETRY [...]

Bristol Myers Squibb Presents Data from CheckMate -648

2021-06-04T13:24:13-05:00June 4th, 2021|

Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -648 trial, in which two Opdivo-based treatment combinations — Opdivo (nivolumab)plus chemotherapy and Opdivo plus Yervoy (ipilimumab) —demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy at the pre-specified interim analysis in patients with unresectable advanced or [...]

Go to Top